Michael W Dae1, Kathleen D Liu2, Richard J Solomon3, Dong W Gao1, Carol A Stillson1. 1. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA. 2. Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA. 3. Division of Nephrology and Hypertension, Department of Medicine, The Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
Abstract
INTRODUCTION: Post-contrast acute kidney injury (PC-AKI) develops in a significant proportion of patients with CKD after invasive cardiology procedures and is strongly associated with adverse outcomes. OBJECTIVE: We sought to determine whether increased intrarenal nitric oxide (NO) would prevent PC-AKI. METHODS: To create a large animal model of CKD, we infused 250 micron particles into the renal arteries in 56 ± 8 kg pigs. We used a low-frequency therapeutic ultrasound device (LOTUS - 29 kHz, 0.4 W/cm2) to induce NO release. NO and laser Doppler probes were used to assess changes in NO content and blood flow. Glomerular filtration rate (GFR) was measured by technetium-diethylene-triamine-pentaacetic acid (Tc-99m-DTPA) radionuclide imaging. PC-AKI was induced by intravenous infusion of 7 cm3/kg diatrizoate. In patients with CKD, we measured GFR at baseline and during LOTUS using Tc-99m-DTPA radionuclide imaging. RESULTS: In the pig model, CKD developed over 4 weeks (serum creatinine [Cr], mg/dL, 1.0 ± 0.2-2.6 ± 0.9, p < 0.01, n = 12). NO and renal blood flow (RBF) increased in cortex and medulla during LOTUS. GFR increased 75 ± 24% (p = 0.016, n = 3). PC-AKI developed following diatrizoate i.v. infusion (Cr 2.6 ± 0.7 baseline to 3.4 ± 0.6 at 24 h, p < 0.01, n = 3). LOTUS (starting 15 min prior to contrast and lasting for 90 min) prevented PC-AKI in the same animals 1 week later (Cr 2.5 ± 0.4 baseline to 2.6 ± 0.7 at 24 h, p = ns, n = 3). In patients with CKD (n = 10), there was an overall 25% increase in GFR in response to LOTUS (p < 0.01). CONCLUSIONS: LOTUS increased intrarenal NO, RBF, and GFR and prevented PC-AKI in a large animal model of CKD, and significantly increased GFR in patients with CKD. This novel approach may provide a noninvasive nonpharmacological means to prevent PC-AKI in high-risk patients.
INTRODUCTION: Post-contrast acute kidney injury (PC-AKI) develops in a significant proportion of patients with CKD after invasive cardiology procedures and is strongly associated with adverse outcomes. OBJECTIVE: We sought to determine whether increased intrarenal nitric oxide (NO) would prevent PC-AKI. METHODS: To create a large animal model of CKD, we infused 250 micron particles into the renal arteries in 56 ± 8 kg pigs. We used a low-frequency therapeutic ultrasound device (LOTUS - 29 kHz, 0.4 W/cm2) to induce NO release. NO and laser Doppler probes were used to assess changes in NO content and blood flow. Glomerular filtration rate (GFR) was measured by technetium-diethylene-triamine-pentaacetic acid (Tc-99m-DTPA) radionuclide imaging. PC-AKI was induced by intravenous infusion of 7 cm3/kg diatrizoate. In patients with CKD, we measured GFR at baseline and during LOTUS using Tc-99m-DTPA radionuclide imaging. RESULTS: In the pig model, CKD developed over 4 weeks (serum creatinine [Cr], mg/dL, 1.0 ± 0.2-2.6 ± 0.9, p < 0.01, n = 12). NO and renal blood flow (RBF) increased in cortex and medulla during LOTUS. GFR increased 75 ± 24% (p = 0.016, n = 3). PC-AKI developed following diatrizoate i.v. infusion (Cr 2.6 ± 0.7 baseline to 3.4 ± 0.6 at 24 h, p < 0.01, n = 3). LOTUS (starting 15 min prior to contrast and lasting for 90 min) prevented PC-AKI in the same animals 1 week later (Cr 2.5 ± 0.4 baseline to 2.6 ± 0.7 at 24 h, p = ns, n = 3). In patients with CKD (n = 10), there was an overall 25% increase in GFR in response to LOTUS (p < 0.01). CONCLUSIONS: LOTUS increased intrarenal NO, RBF, and GFR and prevented PC-AKI in a large animal model of CKD, and significantly increased GFR in patients with CKD. This novel approach may provide a noninvasive nonpharmacological means to prevent PC-AKI in high-risk patients.
Authors: Jennifer C Sullivan; Jennifer L Pardieck; Kelly A Hyndman; Jennifer S Pollock Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-11-04 Impact factor: 3.619
Authors: Sanjay Misra; Jeffery D Gordon; Alex A Fu; James F Glockner; Alejandro R Chade; Jaywant Mandrekar; Lilach Lerman; Debabrata Mukhopadhyay Journal: J Surg Res Date: 2006-06-30 Impact factor: 2.192
Authors: Robert J Siegel; Valentina N Suchkova; Takashi Miyamoto; Huai Luo; Raymond B Baggs; Yoram Neuman; Michael Horzewski; Veijo Suorsa; Sergio Kobal; Todd Thompson; Debra Echt; Charles W Francis Journal: J Am Coll Cardiol Date: 2004-10-06 Impact factor: 24.094
Authors: Lauren Phillips; Alexander H Toledo; Fernando Lopez-Neblina; Roberto Anaya-Prado; Luis H Toledo-Pereyra Journal: J Invest Surg Date: 2009 Jan-Feb Impact factor: 2.533
Authors: Jeremiah R Brown; Michael E Rezaee; Elizabeth L Nichols; Emily J Marshall; Edward D Siew; Michael E Matheny Journal: J Am Heart Assoc Date: 2016-03-15 Impact factor: 5.501